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Abstract 
Interleukin-17A (IL17A), a characteristic cytokine 
produced by the T helper 17 cells (Th17 cells), can 
form either a homodimer or a heterodimer with 
IL17F.  
It is produced not only by Th17 cells, but also by 
cytotoxic CD8+ T cells (Tc17 cells), γδ T cells, 
invariant natural killer T cells (iNKT cells), 
lymphoid tissue inducer cells (LTi cells), and other 
hematopoietic and non-hematopoietic cells. During 
development, these cells exhibit flexible or plastic 
features distinct from those of Th1 and Th2 cells. 
IL17A plays important roles in the pathogenesis of 
autoimmune diseases and in the host defenses 
against bacterial and fungal infections.  
Expression of IL17A and its related factors, as well 
as the infiltration of IL17A-producing cells into the 
tumor microenvironment, has been implicated in 
anti-tumor or pro-tumor effects in various cancers. 
Keywords: Th17 cells, RORγt, STAT3, IL23, 
TGFβ, inflammation 
Identity 
Other names: CTLA8, IL-17, IL-17A, IL17 
HGNC (Hugo): IL17A 
Location: 6p12.2 
Local order: pter - PKHD1 (polycystic kidney and  
hepatic diseases 1) - MIR206 (microRNA 206) - 
MIR133B (microRNA 133b) - IL17A - IL17F 
(interleukin 17F) - SLC25A20P1 (solute carrier 
family 25, member 20 pseudogene 1) - MCM3 
(minichromosome maintenance complex 
component 3) - centromere. 
DNA/RNA 
Note 
IL17A was initially identified in a subtractive 
hybridization screen of a rodent T cell library as 
mouse cytotoxic T lymphocyte-associated antigen 8 
(mCTLA8) (Rouvier et al., 1993), but is now 
recognized as a characteristic cytokine of the Th17 
cell subset, which has effector functions distinct 
from those of Th1 and Th2 cells (Korn et al., 2009; 
Kurebayashi et al., 2013). 
Description 
The IL17A gene spans a region of 4252 bp, 
consisting of three exons. 
Transcription 
The transcript is 1859 bp and has a 45 bp 5' UTR, a 
468 bp coding sequence, and a 1346 bp 3' UTR. 
Pseudogene 
No pseudogenes homologous to this gene exist 
elsewhere in the genome. 
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IL17A gene. The IL17A gene spans a region of 4252 bp, consisting of three exons (untranslated region (UTR), light blue; coding 
region, blue) and two introns (brown). Exons 1, 2, and 3 are 72 bp (45 bp 5' UTR plus 27 bp coding region), 203 bp (all coding 
regions), and 1584 bp (238 bp coding region plus 1346 bp 3' UTR) in length, respectively. The two introns are 1144 bp and 1249 




The IL17A protein is a glycoprotein that can form 
either a disulfide-linked homodimer or a 
heterodimer with the IL17F protein. Members of 
the IL17 protein family (IL17A-F) contain four 
highly conserved cysteine residues on each 
monomer (Kolls and Lindén, 2004; Iwakura et al., 
2011). Structural analysis of the IL17F protein has 
revealed that these four cysteines participate in the 
characteristic cystine-knot formation observed in 
other growth factors such as nerve growth factor 
(NGF), transforming growth factor β2 (TGFβ2) and 
platelet-derived growth factor (PDGF)-BB 
(McDonald and Hendrickson, 1993), although one 
of the canonical disulfides of the cystine-knot is 
absent from the IL17 protein family (Hymowitz et 
al., 2001). Two additional cysteine residues 
participate in homodimer formation via inter-chain 
disulfide bonds. Crystal structures are now 
available for IL17A in complex with an antibody 
(Gerhardt et al., 2009), an IL17F/IL17 receptor A 
complex (Ely et al., 2009) and an IL17A/IL17 
receptor A complex (Liu et al., 2013). 
 
IL17A protein. The IL17A protein (155 amino acids) 
consists of a signal peptide (light green, 23 amino acids) 
and a mature peptide (green, 132 amino acids). Four 
conserved cysteines (Cys) form the intra-chain disulfide 
bonds indicated by black lines (Cys94/Cys144 and 
Cys99/Cys146) (Hymowitz et al., 2001). The two cysteines 
indicated by asterisks (Cys33 and Cys129) participate in 
homodimer formation via inter-chain disulfide bonds. 
Asparagine 68 (Asn68, black circle) is predicted to be 
glycosylated. 
Description 
The IL17A monomer is a peptide consisting of 155 
amino acids. The IL17A peptide comprises a 23 
amino acid signal peptide and a 132 amino acid 
mature peptide. The IL17A homodimer has a 
molecular weight of 35 kD (Kolls and Lindén, 
2004). 
Expression 
IL17A is secreted not only by CD4+ T cells (Th17 
cells), which also produce IL17F, IL21, and IL22 
(Korn et al., 2009; Kurebayashi et al., 2013), but 
also by CD8+T cells (Tc17 cells), γδ T cells, 
invariant natural killer T cells (iNKT cells), innate 
lymphoid cells (ILCs) including lymphoid tissue 
inducer cells (LTi cells), B cells, neutrophils, and 
other non-hematopoietic cells (Cua and Tato, 
2010). These lymphocytes all express the retinoic 
acid receptor-related orphan nuclear receptor C 
(RORC, the human analogue of mouse RORγt, a 
splice variant of the Rorc gene). RORγt is essential 
for IL17A production and the development of 
IL17A-producing cells, at least in lymphocytes, and 
is thus considered a master regulator of IL17A-
producing cells. 
Th17 cells 
Th17 cells are a subset of helper T cells that have 
effector functions distinct from those of Th1 and 
Th2 cells. Early reports showed that stimulation 
with transforming growth factor β1 (TGFβ1) and 
IL6 is required to induce differentiation of IL17-
producing CD4+ T cells (Th17 cells) from naïve 
CD4+ T cells (Korn et al., 2009). More recent 
reports have shown that Th17 cells can be 
categorized into two distinct subsets: conventional 
Th17 cells (Th17(β) cells, also called non-
pathogenic Th17 cells), which differentiate in the 
presence of IL6 and TGFβ1, and Th17(23) cells 
(also called pathogenic Th17 cells), which 
differentiate in the presence of IL6, IL23 and IL1β 
without exogenous TGFβ1 (Ghoreschi et al., 2010; 
Basu et al., 2013; Kurebayashi et al., 2013). IL6 
and IL1β can induce the expression of IL23 
receptor in naïve CD4+ T cells in the absence of 
TGFβ1. Th17(β) cells express IL9, IL10, CCL20, 
and CXCR6 as well as IL17A and IL17F, whereas 
Th17(23) cells express IL22, CCL9 and CXCR3; 
relative to Th17(β) cells, Th17(23) cells make a 
greater contribution to pathogenesis in autoimmune 
diseases (Ghoreschi et al., 2010). Th17 cells 
stimulated with IL23, which is secreted by dendritic 
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cells and macrophages following stimulation with 
Toll-like receptor (TLR) ligands, induce expression 
of TGFβ3, leading to the induction of pathogenic 
Th17(23) cells (Lee et al., 2012). These pathogenic 
Th17 cells are characterized by the expression of T-
bet (TBX21, T-box protein 21), a master regulator 
of Th1-cell development, as well as RORγt. 
Compared with Th1 and Th2 differentiation, Th17-
cell differentiation exhibits plastic or flexible 
features (Oestreich and Weinmann, 2012; Basu et 
al., 2013). TGFβ1 signaling induces the expression 
of both Foxp3 and RORγt in antigen-activated 
naïve CD4+ T cells and is involved in the 
differentiation of both iTreg and Th17 cells. 
Therefore, additional factors determine iTreg and 
Th17 polarization. Furthermore, iTreg and Th17 
cells can transdifferentiate under specific conditions 
(Hoechst et al., 2011). The transition from Th17 
cells to Th1 cells is also induced by IL23 and IL12 
in a STAT4- and T-bet-dependent manner (Lee et 
al., 2009; Mukasa et al., 2010). 
In addition to RORγt and the aforementioned 
cytokines, several transcriptional regulators 
positively regulate Th17 cell differentiation: signal 
transducer and activator of transcription 3 (STAT3), 
BATF (basic leucine zipper transcriptional factor, 
ATF-like), interferon regulatory factor 4 (IRF4), 
Runt-related transcriptional factor 1 (RUNX1), 
RORα and aryl hydrocarbon receptor (AHR, a 
nuclear receptor for a number of low-molecular 
weight chemicals such as the tryptophan 
photoproduct 6-formylindolo[3,2-b]carbazole 
(FICZ)) (Hirahara et al., 2010; Kurebayashi et al., 
2013). Moreover, prostaglandin E2, ATP, and C-
type lectin ligands act on antigen-presenting cells to 
facilitate Th17-cell differentiation. By contrast, IL4, 
interferon-γ (IFNγ), IL27, suppressor of cytokine 
signaling 3 (SOCS3), and STAT5 all suppress 
Th17-cell differentiation. 
Tc17 cells 
CD8+ T cells develop into Tc17 cells in the 
presence of TGFβ1 and either IL6 or IL21, similar 
to the requirements for Th17-cell development 
(Intlekofer et al., 2008). Tc17 cells are also 
characterized by the expression of RORγt, STAT3, 
RORα and IL23R. However, Tc17 cells do not 
express Granzyme B, and they exhibit impaired 
cytotoxic activity relative to conventional cytotoxic 
CD8+T cells (Huber et al., 2009). A recent report 
suggested that TGFβ signaling is not required for in 
vivo differentiation of Tc17 cells (Dwivedi et al., 
2012). 
γδ T cells 
Two distinct subsets of CD27+ or CD27- γδ T cells 
develop in the mouse fetal thymus: co-stimulation 
of TCR and CD27 induces CD27+ γδ T cells to 
express T-bet and produce IFNγ whereas the 
absence of TCR signaling (or weak signaling) 
promotes the development of IL17A-producing 
CD27- γδ T cells, a process controlled by RORγt 
and RUNX1 (Cua and Tato, 2010; Prinz et al., 
2013). Because peripheral CD27-γδ T cells have 
permissive histone modification at loci involved in 
expression of not only Il17a but also Ifng, they can 
produce both IL17A and IFNγ upon stimulation 
with IL1β and IL23 (Schmolka et al., 2013). All 
innate IL17-producing lymphocytes, including γδ T 
cells, iNKT cells and LTi cells, express RORγt and 
develop in an IL6-independent manner (Cua and 
Tato, 2010). 
iNKT cells 
iNKT cells are activated in response to glycolipid 
antigens presented by CD1d (Cua and Tato, 2010; 
Guo et al., 2012). IL17A-producing iNKT cells 
develop in the thymus, and express RORγt and 
IL23R. A recent report suggested that iNKT cells 
can be induced to produce IL17A in the presence of 
TGFβ1 and IL1β (Monteiro et al., 2013). 
LTi cells 
Innate lymphoid cells (ILCs), a family of RAG1/2-
negative lymphoid cells, require the common 
cytokine receptor γ-chain (also known as IL2RG) 
and inhibitor of DNA binding 2 (ID2), a 
transcriptional repressor (Guo et al., 2012; Fuchs 
and Colonna, 2013; Spits et al., 2013). LTi cells, 
which like NK cells are prototypical ILCs, belong 
to the Group 3 ILCs (ILC3s), defined by the 
production of IL17A and/or IL22 (Spits et al., 
2013). ILC3s require the expression of RORγt for 
their development, express IL23R and IL1R, and 
produce IL17A and/or IL22 upon stimulation with 
IL23 or IL1β. 
B cells 
A recent report shows that Trypanosoma crusi 
promotes IL17A production by B cells in human 
and mouse (Bermejo et al., 2013). T. crusi trans-
sialidase mediates addition of sialyl residues onto 
CD45 expressed on B cells, resulting in induction 
of IL17A and F via BTK activation without the 
involvement of the transcriptional factors RORγt 
and AHR. 
Other cells 
Although the details of the underlying signaling 
pathways and transcriptional factors are not known, 
cells other than lymphocytes, such as Paneth cells 
in the gut and CD11b+Gr1+ cells in the injured 
kidney also produce IL17A (Cua and Tato, 2010). 
Localisation 
IL17A is a secreted protein. 
Function 
IL17A is a pro-inflammatory cytokine that acts on a 
variety of cells (e.g., fibroblasts, epithelial cells, 
endothelial cells, and monocytes) to induce the 
production of other cytokines, including IL6, tumor 
necrosis factor-α (TNFα), granulocyte-macrophage 
colony-stimulating-factor (GMCSF), granulocyte 
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colony-stimulating-factor (GCSF), chemokines 
(chemokine (C-X-C motif) ligand 1 (CXCL1), 
CXCL2, CXCL5, and CXCL8), antimicrobial 
peptides (defensins) and matrix metalloproteinases 
(MMP1, MMP3, and MMP13) (Eyerich et al., 
2010; Iwakura et al., 2011). These factors mediate 
the recruitment, activation and migration of 
neutrophils and myeloid cells, and also induce 
angiogenesis and tissue destruction. 
IL17A, IL17F, and the IL17A-IL17F heterodimer 
bind to a heteromeric receptor complex composed 
of IL17 receptor A (IL17RA) and IL17 receptor C 
(IL17RC). IL17RA is expressed at high levels in 
hematopoietic cells and at low levels in epithelial 
cells, fibroblasts, and endothelial cells (Gaffen, 
2009; Iwakura et al., 2011). On the other hand, 
IL17RC is expressed at low levels in hematopoietic 
cells and at high levels in the adrenal gland, 
prostate, liver, and thyroid. IL17RA has higher 
affinity for IL17A than IL17F, whereas IL17RC has 
higher affinity for IL17F than IL17A. Although 
cytokines secreted by most activated helper T cells 
generally stimulate the Janus kinase (JAK)/STAT 
pathway, the IL17-family cytokines stimulate 
signaling pathways involved in the innate immune 
system, such as the TLR signaling pathway 
(Gaffen, 2009; Iwakura et al., 2011). 
IL17 receptors contain a conserved domain, 'similar 
expression to fibroblast growth factor/IL17R' 
(SEFIR), in the cytoplasmic region. This domain is 
similar to the Toll-/IL1R (TIR) domain (Gaffen, 
2009; Iwakura et al., 2011). When the IL17 receptor 
is activated, the adaptor molecule actin-related gene 
1 (ACT1, a U-box E3 ubiquitin ligase) is recruited 
to the SEFIR domain and mediates the lysine 63-
linked ubiquitination of tumor necrosis factor 
receptor-associated factor 6 (TRAF6) (Gaffen, 
2009; Iwakura et al., 2011). Ubiquitinated TRAF6 
then activates the transcriptional factor nuclear 
factor κB (NFκB), various mitogen-activated 
protein (MAP) kinases including ERKs and p38, 
and CCAAT/enhancer-binding proteins (C/EBPβ 
and C/EBPδ). 
IL-17A expression and Th17 cell development are 
remarkably affected not only by microorganisms 
and tumors, but also by several environmental 
factors such as nutrients, metabolites, hypoxia, 
toxins, NaCl concentrations, and circadian rhythm. 
The tryptophan photoproduct FICZ positively 
regulates Th17-cell differentiation through AHR, 
whereas 2,3,7,8-tetrachlorodibezo-p-dioxin 
(TCDD) negatively regulates differentiation 
through that receptor (Quintana et al., 2008; 
Veldhoen et al., 2008). Activation of mTORC1 
(mTOR complex containing mLST8 and Raptor) 
promotes Th17-cell differentiation via positive 
regulation of hypoxia-inducible factor 1α (HIF1α 
expression and the activation of S6 kinase (Barbi et 
al., 2013; Kurebayashi et al., 2013). HIF1α directly 
upregulates expression of RORγt and IL17A. 
Therefore, amino acid deprivation selectively 
blocks Th17-cell development through inhibition of 
mTORC1, whereas hypoxia promotes Th17 
development through the activation of HIF1α. High 
levels of lactic acid, secreted from tumors due to 
the Warburg effect, induce macrophages or 
monocytes to mediate increased IL17A production 
by Th17 cells in an antigen-dependent manner, but 
do not Th17-cell differentiation or proliferation 
(Shime et al., 2008; Yabu et al., 2011). 
The circadian rhythm is controlled by a series of 
feedback loops between the transcriptional factors, 
a CLOCK-BMAL1 complex and REV-ERBα 
(Arjona et al., 2012). The expression of RORγt is 
suppressed by the leucine zipper transcriptional 
factor NFIL3, which is negatively regulated by 
REV-ERBα (Yu et al., 2013). Accordingly, CD4+ T 
cells purified during the day express RORγt at 
higher levels than those purified at night, and tend 
to differentiate into Th17 cells. 
High salt concentration (e.g., 40 mM NaCl) induces 
phosphorylation of p38 and the expression of serum 
glucocorticoid kinase 1 (SGK1) and nuclear factor 
of activated T-cells 5 (NFAT5) to promote the 
IL23-dependent differentiation of pathogenic Th17 
cells (Kleinewietfeld et al., 2013; Wu et al., 2013a). 
In vivo, a high salt diet promotes Th17-cell 
differentiation and exacerbates neuropathy in mice 
with experimental autoimmune encephalomyelitis. 
Homology 
IL17A is a prototypical member of the IL17 family. 
This family includes six proteins: IL17A, IL17B, 
IL17C, IL17D, IL17E (also called IL25), and 
IL17F. Interleukins 17A-F are not homologous to 
any other known proteins. IL17A has the highest 
sequence identity with IL17F (46.5 %). It is less 
similar to the other IL17 family members: IL17B, 





Tumor infiltration by Th17 cells is positively 
correlated with infiltration by Th1 cells, IFNγ-
producing CD8+ cells (Tc1 cells), IL17A- and 
IFNγ-double-positive T cells, and NK cells, but 
negatively correlated with the presence of Treg 
cells (Kryczek et al., 2009a). Increased IL17A 
levels in ascites are well correlated with better 
patient survival and lower grades of ovarian cancer. 
Esophageal cancer 
Note 
Elevated levels of IL17A-producing cells, including 
Th17 cells, in esophageal cancer tissues are 






Atlas Genet Cytogenet Oncol Haematol. 2014; 19(1) 22 
associated with the intratumoral accumulation of 
CD8+ T and NK cells, as well as with better 
prognosis (Lv et al., 2011). 
Prostate cancer 
Note 
In prostate tumors, elevated levels of Th17 cells are 
associated with a lower pathologic Gleason scores 
(Sfanos et al., 2008). However, in prostate cancer 
patients, a higher frequency of CCR4- Th17 cells in 
peripheral blood is correlated with shorter time to 
metastatic progression after immunotherapy with an 




The relationship between IL17A and gastric cancer 
is controversial. Expression of IL17A in peripheral 
blood mononuclear cells (PBMC) and gastric 
cancer tissue is elevated, especially in patients with 
advanced-stage gastric cancer (Zhang et al., 2008; 
Zhuang et al., 2012; Su et al., 2014). One group 
suggested that increased infiltration of Tc17 cells in 
tissues is associated with higher stages and lower 
overall survival rates (Zhuang et al., 2012). Th17 
cells also infiltrate tumors, but the percentage of 
Th17 cells is lower than that of Tc17 cells. 
CXCL12, which is produced by tumors stimulated 
with IL17A, promotes the recruitment of CXCR4-
dependent MDSCs and suppresses the function of 
the cytotoxic CD8+ T cells (Zhuang et al., 2012). 
However, another group's report showed that 
intratumoral expression of IL17A is associated with 
good prognosis (Chen et al., 2011). Several studies 
have examined the relationship between gastric 
cancer risk and a single nucleotide polymorphism 
(SNP) in the IL17A gene promoter region. This 
SNP (rs2275913, G/A SNP, 52051033 bp from 
pter) is located at position -197 relative to the start 
codon within the NFAT-binding motif. The A-
allele is associated with higher IL17A promoter 
activity and higher affinity for NFAT, which plays 
critical roles in the IL17A production, than the G-
allele (Espinoza et al., 2011). Studies of the 
association between rs2275913 and gastric cancer 
have yielded different results in different 
populations. Four groups reported that the AA-
genotype and A-allele of SNP rs2275913 are 
significantly associated with gastric cancer risk in 
Japanese (Shibata et al., 2009), Iranian (Rafiei et 
al., 2013), and Chinese populations (Qinghai et al., 
2014; Zhang et al., 2014a), whereas one Chinese 
group reported that this SNP is not associated with 
total cancer risk or survival in gastric cancer 
patients (Wu et al., 2010). Two studies suggested 
that this SNP is significantly associated with gastric 
cancer risk in Helicobacter pylori-infected patients, 
smokers, or non-cardia gastric cancer patients 
(Qinghai et al., 2014; Zhang et al., 2014a). The TT-
genotype of the SNP rs3748067, which is localized 
in 3' UTR of the IL17A gene (C/T SNP, a position 
at 52055339 bp from pter), was associated with 
increased risk of gastric cancer in two studies 
(Qinghai et al., 2014; Zhang et al., 2014a). 
Colorectal cancer 
Note 
Elevated levels of IL17A-producing cells are 
associated with poor prognosis as a result of 
increased VEGFA expression in colorectal cancer 
patients (Liu et al., 2011; Tosolini et al., 2011; Wu 
et al., 2013b). Furthermore, the A-allele of SNP 
rs2275913 is positively associated with 
susceptibility to colorectal cancer, as well as with 
clinical features as tumor location, tumor 
differentiation, and TNM stage (Omrane et al., 
2014). In a mouse model of colorectal cancer, loss 
of effective barrier function in the transformed 
epithelial cells of colonic adenoma results in the 
infiltration of non-pathogenic bacteria and their 
products, leading to the production of inflammatory 
cytokines (including IL23 and IL17A) and the 
induction of tumor-elicited inflammation, which 




In patients with hepatocellular carcinoma, increased 
intratumoral accumulation of IL17A-producing 
cells is significantly associated with poor prognosis 
and increased tumor vasculogenesis (Zhang et al., 
2009). 
Uterine cervical cancer 
Note 
Levels of Tc17 cells are higher in PBMCs and 
tumors of uterine cervical cancer patients with 
lymph-node metastasis than in patients without 
metastasis (Zhang et al., 2014b). Higher 
accumulation of Tc17 cells in tumors is associated 
with a greater degree of tumor vasculogenesis and 
increased infiltration by Th17 cells and Treg cells. 
In Chinese women, the AA-genotype and A-allele 
of IL17A polymorphism rs2275913 are positively 
associated with susceptibility, peritumoral 
intravascular cancer emboli, and high clinical stage 
(Quan et al., 2012). 
Breast cancer 
Note 
Increased infiltration of IL17A-producing cells in 
tissues is associated with shorter disease-free 
survival in breast cancer patients and higher 
histopathological grades (Chen et al., 2013). 
Among Han Chinese women, the frequency of the 
AA-genotype of the IL17A SNP rs2275913 is also 
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higher in patients than controls (Wang et al., 2012). 
IL17A-producing T cells and Treg cells are 
synchronically increased in peripheral blood and 
tumor tissues of breast cancer patients relative to 
those of healthy individuals (Benevides et al., 
2013). Levels of the angiogenic factors CXCL8, 
MMP-2, MMP-9, and VEGFA, which are induced 
by IL17A, are also elevated in breast cancer tissue. 




Higher levels of IL17A-producing cells are 
associated with poor prognosis and increased 
lymphangiogenesis in non-small cell lung cancer 
tissues (Chen et al., 2010). Although no significant 
relationship between SNP rs2275913 in the IL17A 
gene and lung cancer risk has been observed in the 
total Tunisian population, the A-allele is associated 
with increased lung cancer risk in the male and 
smoker subgroups (Kaabachi et al., 2014). 
Bladder cancer 
Note 
The frequency of the AA-genotype and A-allele of 
SNP rs2275913 in bladder cancer patients is 
significantly higher than in control Han Chinese 
populations (Zhou et al., 2013). This SNP is also 
associated with increased bladder cancer risk in 
males and non-smokers, as well as with invasion of 
bladder cancer. 
Autoimmune and inflammatory 
diseases 
Note 
IL17-producing cells are associated with the 
pathogenesis of many autoimmune and 
inflammatory diseases, such as EAE/multiple 
sclerosis, inflammatory skin diseases/psoriasis, 
inflammatory bowel diseases, ankylosing 
spondylitis, and experimental arthritis/rheumatoid 
arthritis, in both human patients and mouse models 
(Awasthi and Kuchroo, 2009; Korn et al., 2009). 
Recent reports have shown that treatment of 
psoriasis patients with the antibodies that neutralize 
IL17A and IL17A-IL17F heterodimer or block 
IL17RA results in reduction in the affected skin 
area and disease severity (Leonardi et al., 2012; 
Papp et al., 2012). Thus, therapies targeting the 
IL17A signaling pathway are predicted to be 
effective in psoriasis patients. 
Infections 
Note 
Both IL17A and IL17F are preferentially produced 
during infections with the Gram-negative bacteria 
Klebsiella pneumoniae in the lungs and Citrobacter 
rodentium in the colon, the Gram-positive 
bacterium Staphylococcus aureus in the skin, and 
the fungus Candida albicans in the mouth; IL17A 
appears to protect against all of these types of 
infections (Korn et al., 2009; O'Connor et al., 2010; 
Iwakura et al., 2011). During the early response to 
infection, IL17A is predominantly secreted by γδ T 
cells and iNKT cells, and it induces the production 
of antimicrobial peptides such as β-defensins, 
regenerating (REG) proteins, and S100 proteins, as 
well as granulopoietic factors such as GCSF and 
CCL20, from epithelial cells (Cua and Tato, 2010). 
This results in the rapid recruitment of neutrophils 
to sites of infection, which in turn promotes 
efficient pathogen clearance. Later, antigen-specific 
αβ Th17 cells contribute to further responses to 
infection. 
Cancers in mouse models 
Note 
Elevated expression of IL17A and increased 
accumulation of IL17A-producing cells in the 
tumor microenvironment are associated with anti-
tumor or pro-tumor effects in various types of 
cancer in human patients and mouse models (Zou 
and Restifo, 2010). Although IL17A-producing 
cells are not the dominant T-cell subset in the tumor 
microenvironment, their levels are elevated to a 
greater extent in the tumor site than in peripheral 
blood of patients (Kryczek et al., 2009a). Recent 
reports have suggested that the increased 
accumulation of not only Th17 cells, but also Tc17 
(Hinrichs et al., 2009; Zhuang et al., 2012), IL17-
producing γδ T cells (Wakita et al., 2010; Schmolka 
et al., 2013), and ILC3s (Kirchberger et al., 2013), 
regulates tumor development.  
Overexpression of IL17A in tumor cells suppresses 
tumor growth in a cytotoxic T lymphocyte-
dependent manner (Benchetrit et al., 2002). The 
transfer of tumor antigen-specific T cells polarized 
to the IL17-producing phenotype also induces 
eradication of tumor cells by inducing strong CD8+ 
T-cell activation (Martin-Orozco et al., 2009). 
Furthermore, deficiency of IL17A in mice promotes 
growth and metastasis of tumors (Kryczek et al., 
2009b; Martin-Orozco et al., 2009). IL17A-
producing T cells are predicted to induce 
recruitment of other effector cells (e.g., cytotoxic 
CD8+ T cells and NK cells) to tumors by inducing 
expression of CXCL9 and CXCL10 within tumor 
sites (Kryczek et al., 2009a). Moreover, Th17 cells 
induce expression of CCL20, a ligand for 
chemokine (C-C motif) receptor 6 (CCR6), in 
tumor tissues. CCL20 recruits dendritic cells, which 
mediate anti-tumor effects in a CCL20/CCR6-
dependent manner (Martin-Orozco et al., 2009). 
On the other hand, overexpression of IL17A in 
tumors facilitates tumor growth by inducing 
angiogenesis in the tumor microenvironment 
(Numasaki et al., 2003; Numasaki et al., 2005). 
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Furthermore, IL17A-deficient or IL17RA-deficient 
mouse models were used to show that IL17A was 
involved in the promotion of tumor growth via 
induction of myeloid-derived suppressor cells 
(MDSC) (He et al., 2010), activation of IL6-STAT3 
pathway (Wang et al., 2009), and elevated 
angiogenesis (Wakita et al., 2010). The 
discrepancies between anti-tumor and pro-tumor 
effects may be due to the distinct roles of IL17A-
producing cells in different tumors. 
A recent report showed that IL17A is involved in 
tumor resistance to anti-angiogenic therapy 
targeting vascular endothelial growth factor A 
(VEGFA) (Chung et al., 2013). In this case, the 
primary effect of IL17A is the induction of 
granulocyte colony-stimulating factor (GCSF) 
expression in tumor-associated fibroblasts, leading 
to recruitment of MDSC in the tumor 
microenvironment and induction of another 
angiogenic factor, prokineticin 2 (PROK2, Bv8). 
These results suggest that inhibition of IL17A 
function may improve the efficacy of anti-
angiogenic therapies. 
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